NEW YORK (GenomeWeb) – With the US Food and Drug Administration's approval for AstraZeneca's Iressa (gefitinib), metastatic non-small cell lung cancer patients whose tumors have EGFR mutations now have three personalized treatment options.

Importantly for the drug giant, which has been out of the US lung cancer market for a decade, the approval also may serve as a launch pad for it to re-establish its presence with next generation and combination products.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Berkeley researchers have engineered yeast to make the molecule behind the hoppy taste of beer, Quartz reports.

King's College London researchers examine the influence of school type and genetics on academic achievement.

FiveThirtyEight writes that most who take a direct-to-consumer BRCA1/2 genetic test won't learn much from it.

In Science this week: early life experience influence somatic variation in the genome, and more.